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Abstract 20 
 
M3 muscarinic acetylcholine receptor (M3R) plays a crucial role in the secretion 
of saliva from salivary glands. It is reported that some patients with Sjögren’s 
syndrome (SS) carried inhibitory auto-antibodies against M3R. The purpose of 
this study is to clarify the epitopes and function of anti-M3R antibodies in SS. We 25 
synthesized peptides encoding the extracellular domains of human-M3R 
including the N-terminal region, the first, second, and third extracellular loops. 
Antibodies against these regions were examined by ELISA in sera from 42 SS 
and 42 healthy controls. For functional analysis, human salivary gland (HSG) 
cells were pre-incubated with IgG separated from sera of anti-M3R 30 
antibodies-positive SS, -negative SS, and controls for 12 hr. After loading with 
Fluo-3, HSG cells were stimulated with cevimeline hydrochloride, and 
intracellular Ca2+ concentrations ([Ca2+]i) were measured. Antibodies to the 
N-terminal, first, second and third loop were detected in 42.9% (18/42), 47.6% 
(20/42), 54.8% (23/42), and 45.2% (19/42) of SS, while in 4.8% (2/42), 7.1% 35 
(3/42), 2.4% (1/42), and 2.4% (1/42) of controls, respectively. Antibodies to the 
second loop positive SS-IgG inhibited the increase of [Ca2+]i induced by 
cevimeline hydrochloride. Antibodies to the N-terminal positive SS-IgG and 
antibodies to the first loop positive SS-IgG enhanced it, while antibodies to the 
third loop positive SS-IgG showed no effect on [Ca2+]i as well as anti-M3R 40 
antibodies negative SS-IgG. Our results indicated the presence of several B cell 
epitopes on M3R in SS. The influence of anti-M3R antibodies on salivary 
secretion might differ based on these epitopes. 
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Introduction 
 45 
Sjögren’s syndrome (SS) is an autoimmune disease that affects exocrine glands 
including salivary and lacrimal glands. It is characterized by lymphocytic 
infiltration into exocrine glands, leading to dry mouth and eyes. A number of 
autoantibodies, such as anti-SS-A and SS-B antibodies, are detected in patients 
with SS. However, no SS-specific pathologic autoantibodies have yet been 50 
found in this condition.[1]    
Data from recent studies have suggested that some patients with SS carry 
inhibitory autoantibodies directed against muscarinic acetylcholine receptors 
especially M3 muscarinic acetylcholine receptor (M3R).[1] To date, five subtypes 
of muscarinic acetylcholine receptors (M1R-M5R) have been identified, and 55 
M3R is expressed in exocrine glands and plays crucial roles in exocrine 
secretion. Acetylcholine binds to and activates M3R on salivary gland cells, 
causing a rise in intracellular Ca2+ via inositol 1, 4, 5-trisphosphate (IP3) and IP3 
receptors. Consequently, the rise in intracellular Ca2+ activates apical membrane 
Cl- channels and induces salivary secretion.[1] Activation of M3R also induces 60 
trafficking of aquaporin 5 (AQP5) to the apical membrane from the cytoplasm, 
which causes rapid transport of water across the cell membrane.[2] M3R has 
four extracellular domains; the N-terminal region, the first, second, and third 
extracellular loops. Among these domains, the second extracellular loop is 
critical for receptor activation by agonists.[3] Therefore, the second extracellular 65 
loop of M3R has been the focus of our interest, and we reported a subgroup of 
SS patients who had anti-M3R antibodies that recognized the second 
extracellular loop of M3R.[4, 5] Although these data indicate that the second 
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extracellular loop is the target antigen, the precise epitopes are currently 
unknown. A recent study reported that the third extracellular loop represents a 70 
functional epitope bound by IgG derived from SS patients.[6]  
The present study was designed to clarify the precise B cell epitopes of 
M3R and the function of anti-M3R antibodies. For this purpose, we screened 
sera of SS patients for anti-M3R autoantibodies against all four extracellular 
domains of M3R by enzyme-linked immunosorbent assay (ELISA) using 75 
synthetic peptide antigens and performed functional assays of these antibodies 
using human salivary gland (HSG) cells. We assessed the correlation between 
epitopes and function and various clinical features.  
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Materials and Methods 
 80 
Study population  
Serum samples were collected from 42 Japanese patients with SS (15 with 
primary SS and 27 with secondary SS) who had been followed up at the Division 
of Rheumatology, University of Tsukuba Hospital, Ibaraki, Japan. All patients 
with SS satisfied the Japanese Ministry of Health criteria for the diagnosis of SS. 85 
These criteria included four clinicopathological findings: lymphocytic infiltration of 
the salivary or lacrimal glands, dysfunction of salivary secretion, 
keratoconjunctivitis sicca, and presence of anti-SS-A or SS-B antibodies. The 
diagnosis of SS was based on the presence of two or more of the above items. 
We also recruited 42 healthy controls (HC). Approval for this study was obtained 90 
from the local ethics committee and a signed informed consent was obtained 
from each subject.  
 
Synthesis of peptide antigens 
We synthesized different peptides encoding the extracellular domains of 95 
human-M3R. The N-terminal of human-M3R has a 66-mer amino acid sequence, 
and accordingly we divided this domain into three segments. The sequences 
were, MTLHNNSTTSPLFPNISSSWIHSPSDAGLP for N-terminal 1, 
IHSPSDAGLPPGTVTHFGSYNVSRAAGNFS for N-terminal 2, and 
NVSRAAGNFSSPDGTTDDPLGGHTVWQV for N-terminal 3 (Sigma-Aldrich 100 
Japan, Ishikari, Japan). These three peptides were mixed and used for the 
peptide antigens of the N-terminal region. We also synthesized three peptides 
corresponding to the sequences of the three extracellular loops of human-M3R, 
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whose sequences were FTTYIIMNRWALGNLACDLW for the first extracellular 
loop, KRTVPPGECFIQFLSEPTITFGTAI for the second, and 105 
VLVNTFCDSCIPKTFWNLGY for the third (Sigma-Aldrich Japan). As a control 
peptide, we synthesized a peptide corresponding to the sequences of the third 
extracellular loop of human-M5 muscarinic acetylcholine receptor (M5R), whose 
sequences were STFCDKCVPVTLWH (Sigma-Aldrich Japan). As a negative 
peptide, we also synthesized a 25 mer peptide whose sequence was 110 
SGSGSGSGSGSGSGSGSGSGSGSGS (Sigma-Aldrich Japan).  
Enzyme-linked immunosorbent assay (ELISA)  
Peptide solution (100 µl/well at 10 µg/ml) in 0.1 M Na2CO3 buffer, pH 9.6, was 
adsorbed onto a Nunc-Immuno plate (Nalge Nunc International, Rochester, NY) 
overnight at 4°C, and blocked with 5% bovine serum albumin (Wako Pure 115 
Chemical Industries, Osaka, Japan) in phosphate buffered saline (PBS) for 1 hr 
at 37°C. For the dose dependent curve, serum from anti-M3R antibodies positive 
SS and from HC were diluted at 1:25, 1:50, 1:100, 1:200, 1:400, 1:800, and 
1:1600 in blocking buffer, and incubated for 2hr at 37°C. Serum to be examined 
at 1:50 dilution in blocking buffer was also incubated for 2 hr at 37°C. The plates 120 
were then washed six times with 0.05% Tween20 in PBS, and 100 µl of solution 
of alkaline phosphatase-conjugated goat anti-human IgG (Fc; American Qualex, 
San Clemente, CA) diluted 1:1000 in PBS was added for 1 hr at room 
temperature. After nine washes, 100 µl of p-nitrophenyl phosphate (Sigma) 
solution was added at a final concentration of 1 mg/ml as alkaline phosphatase 125 
substrate. Plates were incubated for 30 min at room temperature in the dark, and 
the absorbance at 405nm was measured by plate spectrophotometry. 
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Measurements were performed in triplicate and standardized between 
experiments by using the absorbance value of the positive control.  
 130 
Measurement of salivary secretion  
We assessed salivary secretion by the Gum test. In this test, the volume of 
saliva is measured after chewing gum for 10 min.  
 
Histopathological examination 135 
Histopathological findings of the labial salivary glands were classified according 
to Greenspan grading.[7]  
 
Expression of M3R mRNA in HSG cells 
Total RNA was extracted from HSG cells and cDNA was synthesized by cDNA 140 
synthesis kit (Fermentas International, Ontario, Canada). PCR was performed 
with cDNA using the human-M3R specific primers.[2] The 
human-glyceralaldehyde-3-phosphate dehydrogenase (GAPDH) was amplified 
to assess the cDNA yield. 
 145 
Expression of M3R proteins on the cell surface of HSG cells 
For immunofluorescent analysis, HSG cells were pre-cultured in 2 well chamber 
slides for 48 hr. Without fixation, HSG cells were incubated with the first 
antibodies which were anti-human M3R antibody (goat IgG, polyclonal, Santa 
Cruz Biotechnology, CA) or goat control IgG (Invitorogen Corporation, CA) for 150 
2hr. After washing, HSG cells were incubated with the second antibodies which 
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were FITC conjugated rabbit anti-goat IgG antibodies (IgG, MP Biomedicals, 
CA). Stained HSG cells were observed by fluorescence microscope. 
 
Functional assays 155 
HSG cells (15,000 cells/well) were pre-cultured in 96-well plates for fluorescence 
assays at 37˚C for 48 hr. Then, the cells were pre-incubated with IgG fractions 
separated from sera of anti-M3R antibodies positive 5 SS patients, anti-M3R 
antibodies negative one SS patient, and HC by using protein G column (1.0 
mg/ml) for 12 hr. The referral of the anti-M3R antibodies positive or negative sera 160 
was on the basis of our ELISA results. IgG was washed off, and the HSG cells 
were loaded with Fluo-3, which was a fluorescence probe for calcium, for 1hr. 
Fluo-3 was washed off, and then the HSG cells were analyzed. For Ca2+ influx 
assay, the HSG cells were stimulated with cevimeline hydrochloride which was a 
M3R specific agonist at a final concentration of 20 mM. Changes in intracellular 165 
calcium concentrations ([Ca2+]i) in HSG cells were measured by fluorescence 
plate reader. Maximum changes of [Ca2+]i (peak [Ca2+]i – baseline [Ca2+]i) in IgG 
from SS patients or without IgG were shown as ratiometic data compared to 
maximum change of [Ca2+]i in HC. [2]  
 170 
Statistical analysis 
Differences between groups were examined for statistical significance using the 
Mann-Whitney’s U-test, while differences in frequencies were analyzed by the 
Fisher’s exact probability test. A P value less than 0.05 denoted the presence of 
a statistically significant difference. 175 
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Results 
 
Anti-M3R antibodies in patients with SS and control subjects 
The average age of SS patients was 53.1 ± 13.2 y, that of HC was 33.1 ± 
8.7 y (P<0.05, Mann-Whitney’s U-test). All of 42 SS patients were female, 22 of 180 
HC were female and 20 of HC were male. Among 27 patients with secondary SS, 
11 were complicated with rheumatoid arthritis (RA), 11 with systemic lupus 
erythematosus (SLE), 2 with mixed connective tissue disease (MCTD), and 3 
with other autoimmune diseases.  
     Anti-M3R antibodies were really specific for each M3R peptide, because 185 
the binding activities of sera from SS patients were dose dependent and were 
not in the control sera from healthy subjects. Furthermore, sera from anti-M3R 
antibodies positive SS did not recognize the peptide corresponding to the 
sequences of the third extracellular loop of human-M5R (Figure 1-A). 
Antibodies to the N-terminal region were detected in 42.9% (18/42) of SS 190 
patients but only in 4.8% (2/42) of the control (P<0.05, Fisher’s exact probability 
test). Antibodies to the first extracellular loop were detected in 47.6% (20/42) of 
SS and 7.1% (3/42) of the control (P<0.05, Fisher’s exact probability test). 
Antibodies to the second extracellular loop were detected in 54.8% (23/42) of SS 
and 2.4% (1/42) of the control (P<0.05, Fisher’s exact probability test). 195 
Antibodies to the third extracellular loop were detected in 45.2% (19/42) of SS 
and 2.4% (1/42) of the control (P<0.05, Fisher’s exact probability test). The 
frequencies and titers of anti-M3R antibodies against all extracellular domains 
were significantly higher in SS patients than the control (P<0.05, Fisher’s exact 
probability test for frequencies, Mann-Whitney’s U-test for titers) (Figure 1-B).  200 
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B cell epitopes on the M3R 
Table 1 lists the epitopes of anti-M3R antibodies in patients with SS. Of the 42 
SS patients, 28 had anti-M3R antibodies reactive to at least one B cell epitope 
on the M3R, while the other 14 SS patients did not have any anti-M3R antibodies. 205 
Antibodies to one B cell epitope on the M3R (N-terminal, first extracellular loop, 
second extracellular loop, and third extracellular loop) were detected in one, two, 
two, and one SS patients out of 28 patients, respectively. Antibodies reactive to 
two B cell epitopes (N-terminal and first extracellular loop, N-terminal and 
second extracellular loop, first and second extracellular loop, second and third 210 
extracellular loop) were detected in one, one, two, and two SS patients, 
respectively. Two SS patients showed the presence of antibodies to three B cell 
epitopes (N-terminal and second and third extracellular loop, first and second 
and third extracellular loop). In 50% of the SS patient (14/28), antibodies reactive 
to all four B cell epitopes were detected. Based on these results, we concluded 215 
that anti-M3R antibodies had several B cell epitopes on the extracellular 
domains of M3R, and that some SS patients carried anti-M3R antibodies that 
recognized several extracellular domains of M3R.  
 
Correlation between anti-M3R antibodies and various clinicopathological 220 
features 
Disease duration of SS was shorter among anti-M3R antibodies-positive SS (7.3 
± 7.6 y) than -negative SS (15.5 ± 11.1 y, p<0.05, Mann-Whitney’s U-test). 
The positivity for anti-SS-A antibody and the IgG value in serum was more 
prevalent and higher among anti-M3R antibodies-positive SS than -negative SS 225 
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(p<0.05, Fisher’s exact probability test and Mann-Whitney’s U-test). In contrast, 
there were no differences in age, positivity for anti-SS-B antibody and 
rheumatoid factor, tear volume by Schirmer test, saliva volume by Gum test, 
extra-glandular involvement, and Greenspan grading, between anti-M3R 
antibodies-positive and -negative SS (Table 2). There is no significant 230 
relationship between each B cell epitope and clinical characteristics such as 
saliva secretion. 
 
Expression of M3R mRNA and proteins in HSG cells  
PCR products revealed the expression of M3R mRNA in HSG cells used in the 235 
present study. The expected PCR product for M3R was detected at 201 bp 
(Figure 2-A). Moreover, M3R proteins were detected on HSG cells stained with 
anti-human M3R antibody, whereas they were not found with control IgG (Figure 
2-B). These results indicated that HSG cells expressed M3R molecules on their 
surface.  240 
 
Functional roles of anti-M3R antibodies 
IgG derived from two SS patients positive for anti-M3R antibodies to the second 
extracellular loop inhibited the increase in [Ca2+]i induced by cevimeline 
hydrochloride 16% and 25%, respectively (P<0.05, vs IgG derived from HC, 245 
Mann-Whitney’s U-test) (Figures 3-C, 3-D and 4). In contrast, IgG derived from 
SS patients positive for antibodies to the N-terminal and the first extracellular 
loop enhanced the increase in [Ca2+]i induced by cevimeline hydrochloride 14% 
and 15%, respectively (P<0.05, vs IgG derived from HC, Mann-Whitney’s U-test) 
(Figures 3-A, 3-B, and 4). IgG derived from a SS patient positive for antibodies to 250 
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the third extracellular loop had no effect on [Ca2+]i as well as IgG derived from 
anti-M3R antibodies-negative SS patient (Figures 3-E and 4). 
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Discussion 
Recently, anti-M3R antibodies have been the focus of interest in rheumatology, 
because of their potential pathogenic role, use as diagnostic markers, and being 255 
therapeutic targets in patients with SS.[1] Several methods have been used to 
detect anti-M3R antibodies in SS patients.[1] In functional assays using smooth 
muscles, IgG fractions from patients with SS (SS-IgG) inhibited 
carbachol-evoked or nerve-evoked bladder or colon contractions.[8, 9] In 
salivary gland cells, SS-IgG inhibited the rise in [Ca2+]i induced by carbachol, 260 
and also inhibited pilocarpine-induced AQP5 trafficking to the apical membrane 
from the cytoplasm.[2] The inhibitory actions of SS-IgG on the rise in [Ca2+]i was 
acutely reversible.[10] Anti-M3R antibodies from SS patients can be detected by 
immunofluorescent analysis using rat lacrimal glands [11], and by flow cytometry 
using the M3R-transfected CHO cell line.[12] Moreover, anti-M3R antibodies in 265 
sera of SS patients were detected by ELISA using synthetic peptides or 
recombinant proteins of the second extracellular loop of M3R.[13] We reported 
previously the presence of anti-M3R antibodies in a group of patients with SS, 
which recognized the second extracellular loop by ELISA using synthetic 
peptides.[4, 5]  270 
In the present study, we established a standard method to detect 
anti-M3R antibodies that can be used for screening large patient populations. 
Functional assays and flow cytometry are too laborious for routine use. Although 
ELISA is easy, the results from some ELISA systems used for screening 
anti-M3R antibodies differ widely with regard to the prevalence of anti-M3R 275 
antibodies (from 11 to 90%).[4, 14] Furthermore, Cavill et al. [15] reported failure 
to detect anti-M3R antibodies by ELISA using synthetic peptides. In the present 
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study, we reported higher frequencies and titers of anti-M3R antibodies against 
all extracellular domains in SS patients than the control. The prevalence of 
anti-M3R antibodies against the second extracellular loop in SS (55%) 280 
determined in the present study was much higher than that reported in our 
previous study (11%).[4] The reason for this difference is probably related to the 
change in the methodology, such as increased sensitivity resulting from purity of 
the synthetic peptides, modification of the washing procedure, or other factors 
introduced in the modified ELISA system.  285 
In the present study, we also determined the precise B cell epitopes of 
M3R molecules. B cell epitopes in the present study are areas including peptides 
recognized by anti-M3R antibodies, although we do not know that these linear 
peptides are really conformational epitopes or not. However, we showed 
anti-M3R antibodies against these linear epitopes exactly influenced Ca influx 290 
via M3R in HSG cells. Therefore, we suggest that these linear peptides might 
consist of the conformational epitopes on the M3R. Several B cell epitopes were 
identified on the extracellular domains, and some SS patients were reactive to 
several extracellular domains other than the second extracellular loop. The 
second extracellular loop of M3R has been the focus of our interest in epitopes 295 
and function of anti-M3R antibodies.[4, 5, 9, 10] Recently, Koo et al. [6] reported 
that the third extracellular loop represents a functional epitope bound by SS-IgG. 
In contrast to these results, we found in the present study that antibodies to the 
second extracellular loop of M3R inhibited the increase of [Ca2+]i induced by 
cevimeline hydrochloride in a functional assay using HSG cells. This inhibitory 300 
effect of anti-M3R antibodies might explain the reduction in salivary secretion in 
some SS patients. Our data also demonstrated that antibodies against the third 
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extracellular loop did not have an effect on the increase in [Ca2+]i, while 
antibodies against the N-terminal and first extracellular loop enhanced the 
increase in [Ca2+]i. These results indicate that the effects of anti-M3R antibodies 305 
on the secretion of saliva could be different from these epitopes, although further 
experiments using antibodies from more patients are necessary.   
Although the molecular mechanism on the difference among individual B 
cell epitopes have not elucidated, we could propose the following three 
possibilities. The first possibility is that antibodies against the second 310 
extracellular domain of M3R directly inhibit the intracellular signal pathway, 
resulting in the decrease of Ca2+ influx and reduction of saliva. In contrast, 
antibodies against N-terminal region and the first extracellular domain of M3R 
might enhance the intracellular signaling and increase of Ca2+ influx. The second 
is that anti-M3R antibodies binding to the second extracellular domain could 315 
inhibit M3R agonist, then antibodies indirectly suppress the stimulation of Ca2+ 
influx. The third is that anti-M3R antibodies influence on the expression of M3R 
molecules on HSG. Some antibodies which targets are N-terminal region or the 
first extracellular loop of M3R may be able to up-regulate the expression of M3R 
and enhance Ca2+ influx, whereas the other antibodies against the second 320 
extracellular domain might down-regulate the expression of M3R on HSG, 
resulting in reduction of Ca2+ influx. Exactly, it has been reported that the 
expression of M3R in salivary glands could be affected by anti-M3R antibodies in 
patients with SS.[1] Further experiments on the effect of anti-M3R antibodies on 
M3R signaling, the binding to M3R agonist, and the influence on M3R 325 
expression should shed light on the mechanism of the different function of 
anti-M3R antibodies. 
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We reported previously the presence of anti-M3R antibodies that 
recognized the second extracellular loop in SS patients but not in patients with 
RA or SLE, suggesting that anti-M3R antibodies could be potentially used as 330 
diagnostic markers for SS.[4] However, Kovacs et al. [14] reported the detection 
of anti-M3R antibodies in 35% of their RA patients and 32% of SLE. These 
conflicting results emphasize the need to examine the precise prevalence of 
anti-M3R antibodies in other autoimmune diseases using our modified ELISA 
system. 335 
The correlation between anti-M3R antibodies and clinical features is still unclear. 
The previous study reported leukopenia was more common in anti-M3R 
antibodies-positive than in -negative patients with primary SS.[14] Our 
observations in the present study showed that the positivity for anti-SS-A 
antibody and IgG values in serum was more prevalent and higher in anti-M3R 340 
antibodies-positive SS patients than -negative SS patients. The disease duration 
of SS was shorter among anti-M3R antibodies-positive SS than -negative SS, 
however there was no difference in other clinical and histological features 
between anti-M3R antibodies-positive and -negative SS patients. We could not 
detect any significant relationship between each B cell epitope and clinical 345 
characteristics such as saliva secretion. 
In conclusion, these findings support the notion of presence of several B 
cell epitopes on M3R in SS patients and that some SS patients are reactive to 
several extracellular domains of the M3R. It is possible that some anti-M3R 
antibodies alter salivary secretion in SS via M3R, and especially antibodies 350 
against the second extracellular loop of the M3R could suppress the increase in 
[Ca2+]i induced by agonists of the M3R, resulting in reduction of salivary 
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secretion. Therefore, anti-M3R antibodies might play pathogenic roles in salivary 
secretion abnormalities characteristic of patients with SS． 
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Figure Legends 
 405 
Figure 1. 
(A) The dose dependent curve on anti-M3R antibodies. 
M3R and M5R peptide-specific absorbance values at 405 nm (∆absorbance) 
were calculated for each serum sample by subtracting the absorbance value of 
the negative peptide from that of the peptides encoding the extracellular 410 
domains of human-M3R and M5R. The clear dose response of M3R 
peptide-specific absorbance to changes on serum concentrations was shown in 
serum from anti-M3R antibodies positive Sjögren’s syndrome (SS), but not in 
serum from healthy control (C). The clear dose response of the third extracellular 
loop of M5R-specific absorbance to changes on serum concentrations was not 415 
shown in serum from anti-M3R antibodies positive SS. 
 
(B) Anti-M3R antibodies in patients with SS and control subjects. 
M3R peptide-specific absorbance values at 405 nm (∆absorbance) in Sjögren’s 
syndrome (SS) and healthy control (C). The cut-off l vel between negative and 420 
positive values was the mean+2 SD value of the normal control (gray line). The 
prevalence and titers of anti-M3R antibodies against all extracellular domains 
were significantly higher in patients with SS than control subjects (Fisher’s exact 
probability test for prevalence, Mann-Whitney’s U-test for titers). N; N-terminal 
region, 1st; first extracellular loop, 2nd; second extracellular loop, 3rd; third 425 
extracellular loop. 
Figure 2. (A) Expression of M3R mRNA in HSG cells.  
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(B) Expression of M3R proteins on the surface of HSG cells detected by 
immunofluorescent analysis. 
Figure 3.  430 
Functional analysis of anti-M3R antibodies in SS patients. 
(A) and (B) 
IgG derived from SS patient with anti-M3R antibodies to the N-terminal region 
and the first extracellular loop enhanced the increase in [Ca2+]i induced by 
cevimeline hydrochloride 14% and 15 %, respectively, compared to IgG from 435 
healthy control (HC). The traces were representative traces, which were 
performed in triplicate and three independent experiments with each IgG. HSG 
cells were stimulated with cevimeline hydrochloride (20 mM) at time 10 seconds. 
IgG-; without IgG, HC; IgG derived from healthy control, M3R-SS; IgG derived 
from SS patient negative for anti-M3R antibodies, N+SS; IgG derived from SS 440 
patient positive for anti-M3R antibodies to the N-terminal region, 1st+SS; IgG 
derived from SS patient positive for anti-M3R antibodies to the first extracellular 
loop.  
(C) and (D)  
IgG derived from two SS patients positive for antibodies to the second 445 
extracellular loop inhibited the increase in [Ca2+]i induced by cevimeline 
hydrochloride 16% and 25%, respectively，compared to IgG from HC. The 
traces were representative traces, which were performed in triplicate and three 
independent experiments with each IgG. 2nd+SS; IgG derived from SS patient 
positive for anti-M3R antibodies to the second extracellular loop.  450 
(E)  
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IgG derived from SS patient positive for antibodies to the third extracellular loop 
had no effect on the increase in [Ca2+]i induced by cevimeline hydrochloride. The 
traces were representative traces, which were performed in triplicate and three 
independent experiments with each IgG. 3rd+SS; IgG derived from SS patient 455 
positive for antibodies to the third extracellular loop. 
 
Figure 4.  
Summary of B cell epitopes on M3R and the function of anti-M3R 
antibodies in SS patients. 460 
Mean ± SD values of maximum change in [Ca2+]i (peak [Ca2+]i – baseline [Ca2+]i) 
induced by cevimeline hydrochloride in IgG from SS patients or without IgG were 
shown as a ratio compared to maximum change of [Ca2+]i in healthy control (HC). 
The maximum change in HC was described as 1.0. Data were averaged of 
triplicate and three independent experiments. *; P<0.05, vs IgG derived from HC, 465 
Mann-Whitney’s U-test, HC, IgG-, M3R-SS, N+SS, 1st+SS, 2nd+SS, and 3rd+SS; 
the same as in Figure 3. 
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Table 1  
B cell epitopes on the M3R
N; N-terminal, 1st; f irst extracellular loop, 2nd; second extracellular loop, 3rd; thrid
extracellular loop, +; positiv e f or anti-M3R antibodies, -; negativ e for anti-M3R 
antibodies
N
+
-
-
-
+
+
-
-
+
-
+
1st 2nd 3rd
-
+
-
-
+
-
+
-
-
+
+
-
-
+
-
-
+
+
+
+
+
+
-
-
-
+
-
-
-
+
+
+
+
Number of cases
1 case 
2 cases
2 cases
1 case
1 case
1 case
2 cases
2 cases
1 case
1 case
14 cases
Total number of cases 28 cases
Number of B cell 
epitopes on the M3R
1
2
3
4
B cell epitopes on the M3R
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P<0.0515.5 ± 11.1 7.3 ± 7.6 Disease duration ( y)
P<0.051427 ± 515 2013 ± 767 IgG (mg/dl)
N.S50.046.4Rheumatoid factor (%)
N.S8.8 ± 5.18.3 ± 7.8Gum tes t (ml/10 min)
N.S4.2 ± 5.04.4 ± 6.2 Schirmer test
(mm/5 min)
N.S66.783.3
Extra-glandular 
involvements in primar y 
SS (%)
3.0 ± 0.8
14.3
57.1
56.4 ± 12.1
3/11
Negative SS
N=14
N.S3.1 ± 0.5Histological exami nation
(Greenspan grading)
N.S21.4Anti-SSB (%)
P<0.0592.9Anti-SSA (%)
N.S51.4 ± 12.1Age (y)
N.S12/16Primar y/Secondar y
P Val uePositi ve SS
N=28
Table 2  
Clinicopathological Features in Anti-M3R Antibodies-
Positive SS and -Negative SS Patients                 
N.S; not statistically  signif icant
 470 
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Figure 1. 
(A) The dose dependent curve on anti-M3R antibodies. 
M3R and M5R peptide-specific absorbance values at 405 nm (∆absorbance) were calculated for each 
serum sample by subtracting the absorbance value of the negative peptide from that of the peptides 
encoding the extracellular domains of human-M3R and M5R. The clear dose response of M3R 
peptide-specific absorbance to changes on serum concentrations was shown in serum from anti-M3R 
antibodies positive Sjögren’s syndrome (SS), but not in serum from healthy control (C). The clear 
dose response of the third extracellular loop of M5R-specific absorbance to changes on serum 
concentrations was not shown in serum from anti-M3R antibodies positive SS. 
(B) Anti-M3R antibodies in patients with SS and control subjects. 
M3R peptide-specific absorbance values at 405 nm (∆absorbance) in Sjögren’s syndrome (SS) and 
healthy control (C). The cut-off level between negative and positive values was the mean+2 SD 
value of the normal control (gray line). The prevalence and titers of anti-M3R antibodies against all 
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extracellular domains were significantly higher in patients with SS than control subjects (Fisher’s 
exact probability test for prevalence, Mann-Whitney’s U-test for titers). N; N-terminal region, 1st; 
first extracellular loop, 2nd; second extracellular loop, 3rd; third extracellular loop. 
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Figure 2.  
(A) Expression of M3R mRNA in HSG cells.  
(B) Expression of M3R proteins on the surface of HSG cells detected by immunofluorescent analysis. 
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Figure 3.  
Functional analysis of anti-M3R antibodies in SS patients. 
(A) and (B) 
IgG derived from SS patient with anti-M3R antibodies to the N-terminal region and the first 
extracellular loop enhanced the increase in [Ca2+]i induced by cevimeline hydrochloride 14% and 
15 %, respectively, compared to IgG from healthy control (HC). The traces were representative 
traces, which were performed in triplicate and three independent experiments with each IgG. HSG 
cells were stimulated with cevimeline hydrochloride (20 mM) at time 10 seconds. IgG-; without IgG, 
HC; IgG derived from healthy control, M3R-SS; IgG derived from SS patient negative for anti-M3R 
antibodies, N+SS; IgG derived from SS patient positive for anti-M3R antibodies to the N-terminal 
region, 1st+SS; IgG derived from SS patient positive for anti-M3R antibodies to the first 
extracellular loop.  
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(C) and (D)  
IgG derived from two SS patients positive for antibodies to the second extracellular loop inhibited 
the increase in [Ca2+]i induced by cevimeline hydrochloride 16% and 25%, respectively，compared 
to IgG from HC. The traces were representative traces, which were performed in triplicate and three 
independent experiments with each IgG. 2nd+SS; IgG derived from SS patient positive for anti-M3R 
antibodies to the second extracellular loop.  
(E)  
IgG derived from SS patient positive for antibodies to the third extracellular loop had no effect on 
the increase in [Ca2+]i induced by cevimeline hydrochloride. The traces were representative traces, 
which were performed in triplicate and three independent experiments with each IgG. 3rd+SS; IgG 
derived from SS patient positive for antibodies to the third extracellular loop. 
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Figure 4.  
Summary of B cell epitopes on M3R and the function of anti-M3R antibodies in SS patients. 
Mean ± SD values of maximum change in [Ca2+]i (peak [Ca2+]i – baseline [Ca2+]i) induced by 
cevimeline hydrochloride in IgG from SS patients or without IgG were shown as a ratio compared to 
maximum change of [Ca2+]i in healthy control (HC). The maximum change in HC was described as 
1.0. Data were averaged of triplicate and three independent experiments. *; P<0.05, vs IgG 
derived from HC, Mann-Whitney’s U-test, HC, IgG-, M3R-SS, N+SS, 1st+SS, 2nd+SS, and 3rd+SS; 
the same as in Figure 3. 
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